Edwards Lifesciences (EW) Accounts Payables (2009 - 2026)

Edwards Lifesciences' Accounts Payables history runs 18 years deep, the most recent figure standing at $181.1 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 5.05% year-over-year to $181.1 million; the TTM figure through Mar 2026 stood at $181.1 million (up 5.05% YoY), while the FY2025 annual figure was $227.5 million, up 15.25% from the prior year.
• Accounts Payables was $181.1 million for Q1 2026 at Edwards Lifesciences, down from $227.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $227.5 million in Q4 2025 to a low of $154.9 million in Q3 2022.
• Historically, Accounts Payables has averaged $182.7 million across 5 years, with a median of $181.1 million in 2026.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables slumped 81.13% in 2022, then climbed 23.05% in 2023.
• A 5-year view of Accounts Payables shows it stood at $201.9 million in 2022, then dropped by 7.58% to $186.6 million in 2023, then advanced by 5.79% to $197.4 million in 2024, then grew by 15.25% to $227.5 million in 2025, then slipped by 20.4% to $181.1 million in 2026.
• The last three Accounts Payables figures came in at $181.1 million (Q1 2026), $227.5 million (Q4 2025), and $165.0 million (Q3 2025), per Business Quant data.